Comment on 'Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?'
- PMID: 32371810
- PMCID: PMC7236845
- DOI: 10.1097/HJH.0000000000002481
Comment on 'Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?'
Conflict of interest statement
There are no conflicts of interest.
Comment on
-
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?J Hypertens. 2020 May;38(5):781-782. doi: 10.1097/HJH.0000000000002450. J Hypertens. 2020. PMID: 32195824 No abstract available.
References
-
- Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID- 19 pandemic? J Hypertens 2020; 38:781–782. - PubMed
-
- Brosnihan KB, Neves LA, Chappell MC. Does the angiotensin-converting enzyme (ACE)/ACE2 balance contribute to the fate of angiotensin peptides in programmed hypertension? Hypertension 2005; 46:1097–1099. - PubMed
-
- de Albuquerque Rocha N, Neeland IJ, McCullough PA, Toto RD, McGuire DK. Effects of sodium glucose co-transporter 2 inhibitors on the kidney. Diab Vasc Dis Res 2018; 15:375–386. - PubMed
-
- Romani-Perez M, Outeirino-Iglesias V, Moya CM, Santisteban P, Gonzalez-Matias LC, Vigo E, et al. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology 2015; 156:3559–3569. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
